Related Experiment Video

Updated: Mar 16, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

[Association between genetic variants in the adiponectin gene and premature myocardial infarction]

M Zhang1, Y Peng, S Z Lyu

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|August 18, 2016
PubMed

Insights

Certain adiponectin gene variations, specifically rs2241766T>G and rs12629945G>A, are linked to premature myocardial infarction (PMI) risk in the Chinese Han population. The rs2241766T>G polymorphism is associated with lower adiponectin levels and increased PMI risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Premature myocardial infarction (PMI) poses a significant health burden.
  • Adiponectin, a key adipokine, plays a role in cardiovascular health.
  • Genetic variations in the adiponectin gene may influence PMI susceptibility.

Purpose of the Study:

  • To investigate the association between adiponectin gene single nucleotide polymorphisms (SNPs) and the risk of premature myocardial infarction (PMI).
  • To explore the relationship between plasma adiponectin levels and identified adiponectin gene polymorphisms in PMI patients and controls.

Main Methods:

  • A case-control study involving 306 PMI patients and 412 controls from Beijing Anzhen Hospital.
  • Genotyping of 17 adiponectin gene SNPs using mass spectrometry.
  • Measurement of plasma adiponectin concentrations via enzyme-linked immunoassay and statistical analysis (Chi-squared test, logistic regression).

Main Results:

  • No significant differences in overall allele or genotype frequencies between PMI patients and controls.
  • rs2241766T>G polymorphism showed a significant association with increased PMI risk (additive model, OR=1.446).
  • rs12629945G>A polymorphism was significantly associated with PMI risk (dominant model, OR=1.609).
  • PMI patients exhibited significantly lower plasma adiponectin levels compared to controls (P=0.042).
  • The rs2241766T>G homozygous genotype (GG) was linked to lower adiponectin levels (P=0.032).

Conclusions:

  • Adiponectin gene polymorphisms rs2241766T>G and rs12629945G>A are associated with premature myocardial infarction in the Chinese Han population.
  • The rs2241766T>G polymorphism is implicated in reduced plasma adiponectin levels and elevated PMI risk.
Abstract

More Related Videos

A Modified Simple Method for Induction of Myocardial Infarction in Mice04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

4.7K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
73
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K